BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Search i

Search help

  • Enter one or more search terms in the search field. Upper and lower case are not relevant.
  • As soon as you have entered three letters in the search field, various search words will be suggested from which you can choose one.
  • If you are searching for a certain group of words, put these words in double quotes. The hits will then contain the words in the order you entered, e.g. "medicines for children".
  • Multiple search terms can also be combined with the Boolean operators AND and OR. When using the operator AND, the results contain the intersection of all search terms. When using the operator OR, the hits contain one of the search terms or only individual search terms. The result set is therefore significantly larger. Please note that these operators must be written in capital letters.

  • If you receive a (too) large number of hits as a result of your search, you can narrow it down by using filters. These filter options appear to the left of the search results and are subdivided into:

    • category (e.g. safety of medicinal products, medical devices, code systems)
    • format (e.g. download, risk information, DHPCs)
    • time interval (e.g. last 30 days, older than ...)
  • Selected filters can be removed individually or all at once ("Show all results").
  • By default, search results are sorted by relevance, but they can also be sorted chronologically ("Latest entries first" or "Oldest entries first").

Enter search term

443 results

Filter

Results per page: 10 20 30

Sorting:

Latest entries first

Relevance

Latest entries first(selected sorting)

Oldest entries first

Selected filter

Dear Doctor Letter (Rote-Hand-Brief) on Atorvastatin Basics film-coated tablets ® (atorvastatin): Recall of all batches of the medicinal product currently in circulation PDF, 271KB, File is accessible Date: 03. May 2012 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: atorvastatin

The maximum daily dose for children (point 3 of the Package Leaflet) is incorrectly stated as "maximum dose of 80 mg once daily" instead of "maximum dose of 20 mg once daily".

Dear Doctor Letter (Rote-Hand-Brief) on Carbopaltin onkovis® 10 mg/ml concentrate for solution for infusion (carboplatin): Possible crystallisation of the active substance PDF, 85KB, File is accessible Date: 19. April 2012 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: carboplatin

Due to the danger of a substance-specific crystallisation of the active substance, the solution must be examined for the absence of particles and turbidity prior to use.

Dear Doctor Letter (Rote-Hand-Brief) on Carbomedac® 10 mg/ml concentrate for solution for infusion (carboplatin): Possible crystallisation of the active substance PDF, 45KB, File is accessible Date: 19. April 2012 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: carboplatin

Due to the danger of a substance-specific crystallisation of the active substance, the solution must be examined for the absence of particles and turbidity prior to use.

Dear Doctor Letter (Rote-Hand-Brief) on Alimta® (pemetrexed): Batch recall PDF, 332KB, File is accessible Date: 10. April 2012 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: pemetrexed

Alimta® 500 mg batches recalled due to a possible microbial contamination with Methylobacterium sp. which was discovered during routine controls. In Germany, this concerns batch A931727G and certain imported batches.

Dear Doctor Letter (Rote-Hand-Brief) on Protelos® (strontium ranelate): New contraindications PDF, 2MB, File is accessible Date: 04. April 2012 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: strontium ranelate

The pharmaceutical entrepreneur is sending out information on new contraindications and warnings for the use of Protelos® (strontium ranelate). These changes also apply to Osseor®.

Information Letter on Pegasys® (pegylated interferon alfa 2a) pre-filled syringes: Possible shortage PDF, 800KB, File is accessible Date: 04. April 2012 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: pegylated interferon alfa 2a

Possible shortage of the pharmaceutical form Pegasys® pre-filled syringes and recommendations for healthcare professionals. Prefilled pens are not affected.

Information Letter on Viaspan® (organ preservation solution): Possible contamination of product during the manufacture PDF, 113KB, File is accessible Date: 04. April 2012 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: organ preservation solution

Since alternative products are licensed in Germany, all potentially contaminated batches of ViaSpan® are recalled in Germany as a precautionary measure. Close medical monitoring after transplantation is recommended for affected patients by way …

Dear Doctor Letter (Rote-Hand-Brief) on Perfalgan® 10 mg/ml solution for infusion (paracetamol i.v.): Risk of accidental overdosage PDF, 387KB, File is accessible Date: 27. March 2012 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: paracetamol i.v.

The pharmaceutical manufacturer again refers to the risk of an accidental overdosage of Perfalgan® 10 mg/ml solution for infusion in neonates and infants as well as in underweight adults.

Dear Doctor Letter (Rote-Hand-Brief) on Samsca® (tolvaptan): Risk of too rapid rise of serum sodium PDF, 585KB, File is accessible Date: 27. March 2012 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: tolvaptan

The pharmaceutical manufacturer issues information on the risk of a too rapid rise of serum sodium levels due to the use of Samsca® (tolvaptan) and on how this risk can be reduced.

Information Letter on Vfend® 200 mg powder for solution for infusion (voriconazole): Temporary shortage PDF, 47KB, File is accessible Date: 12. March 2012 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: voriconazole

It is recommended to limit the use of the product to patients without alternative treatment options. An information letter with treatment recommendations has been circulated to treating physicians and pharmacies concerned.